Results 111 to 120 of about 47,533 (300)

Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. [PDF]

, 2015
BackgroundDemethylation process is necessary for the expression of various factors involved in chemotherapy cytotoxicity or resistance. Platinum-resistant cells may have reduced expression of the copper/platinum transporter CTR1.
Culotta, Kirk, Falchook, Gerald, Fu, Siqing, He, Guangan, Hess, Kenneth, Issa, Jean-Pierre J, Jelinek, Jaroslav, Kurzrock, Razelle, Naing, Aung, Piha-Paul, Sarina, Said, Rabih, Siddik, Zahid H, Stewart, David J, Tsimberidou, Apostolia M, Wistuba, Ignacio, Zinner, Ralph   +15 more
core   +2 more sources

Dragon (RGMb) induces oxaliplatin resistance in colon cancer cells

Oncotarget, 2016
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and a major cause of cancer mortality. Chemotherapy resistance remains a major challenge for treating advanced CRC. Therefore, the identification of targets that induce drug resistance is a priority for the development of novel agents to overcome resistance.
Shi, Ying, Huang, Xiao-Xiao, Chen, Guo-Bin, Wang, Ying, Zhi, Qiang, Liu, Yuan-Sheng, Wu, Xiao-Ling, Wang, Li-Fen, Yang, Bing, Xiao, Chuan-Xing, Xing, Hui-Qin, Ren, Jian-Lin, Xia, Yin, Guleng, Bayasi   +13 more
openaire   +3 more sources

Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer [PDF]

JNCI: Journal of the National Cancer Institute, 2013
A major problem in cancer chemotherapy is the existence of primary resistance and/or the acquisition of secondary resistance. Many cellular defects contribute to chemoresistance, but epigenetic changes can also be a cause.A DNA methylation microarray was used to identify epigenetic differences in oxaliplatin-sensitive and -resistant colorectal cancer ...
C. Moutinho, A. Martinez Cardús, C. Santos, V. Navarro Pérez, E. Martínez Balibrea, E. Musulen, F. . J. Carmona, A. Sartore Bianchi, A. Cassingena, S. Siena, E. Elez, J. Tabernero, R. Salazar, A. Abad, M. Esteller   +14 more
openaire   +4 more sources

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

Advanced NanoBiomed Research, EarlyView.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source

Development of a prognostic model for chemotherapy response and identification of TNFAIP2 as a target in colorectal cancer

Scientific Reports
Oxaliplatin, a key chemotherapeutic agent, often induces resistance in colorectal cancer (CRC) treatment, highlighting the urgent need for reliable biomarkers to predict treatment efficacy.
Cheng Zhou, Chuan-Hai Xu, Min Xu, Xin-Kun Huang, Bin Zhu   +4 more
doaj   +1 more source

Exosomal transfer of macrophage-derived miR-223 confers oxaliplatin resistance in gastric cancer

Zhongguo aizheng zazhi, 2021
Background and purpose: Chemotherapy resistance is an important factor resulting in poor prognosis of gastric cancer patients. The elucidation of molecular mechanisms underlying chemoresistance is helpful to provide new therapeutic strategy, which has ...
郑培明, 李俊蒙, 张　鹏, 高　岚   +3 more
doaj  

Intraperitoneal chemotherapy for peritoneal metastases : an expert opinion

, 2020
Introduction: The rationale for intraperitoneal (IP) drug delivery for patients with peritoneal metastases (PM) is based on the pharmacokinetic advantage resulting from the peritoneal-plasma barrier, and on the potential to adequately treat small, poorly
Braet, Helena, Ceelen, Wim, Remaut, Katrien, Van Ramshorst, Gabrielle, Willaert, Wouter   +4 more
core   +1 more source

Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX [PDF]

, 2018
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with lack of predictive biomarkers. We conducted a study to assess DNA damage repair (DDR) gene mutations as a predictive biomarker in PDAC patients treated with FOLFIRINOX ...
Gbolahan, Olumide, Hancock, Brad A., O'Neil, Bert H., Radovich, Milan, Sehdev, Amikar, Shahda, Safi, Stanley, Melissa, Wan, Jun, Wu, Howard H.   +8 more
core   +1 more source

LncRNA PCGEM1 mediates oxaliplatin resistance in hepatocellular carcinoma via miR-129-5p/ETV1 axis in vitro [PDF]

, 2021
Jie Chen, Daiyue Yuan, Qingya Hao, Dongmei Zhu, Zhong Chen   +4 more
openalex   +1 more source

Mechanism of Overcoming Oxaliplatin Resistance Using HT29 Subcloning [PDF]

, 2020
Abstract Background: Cancer cells are different from normal healthy cells even though they reside within the same tissue and adapt to others. This intra-tumoral heterogeneity is the reason for chemo-resistance, and the emergence of one or more clones, which are resistant to chemotherapeutic drugs, causing clonal outgrowth to form recurrent ...
Jisu Lee, MI YOON KIM, Woomi Yang, Il-woung Kim, Seung-Kiel Park, Jong-Il Park   +5 more
openaire   +1 more source